PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 2, 2021Journal of Clinical Medicine40 citationsOpen Access

Prognostic Role of TAPSE to PASP Ratio in Patients Undergoing MitraClip Procedure

BTBlanca Trejo‐VelascoRERodrigo Estévez‐LoureiroFCFernando Carrasco‐Chinchilla

Key Result

A TAPSE/PASP ratio ≤ 0.35 was associated with higher rates of heart failure readmissions and all-cause mortality in patients undergoing MitraClip therapy (Log-Rank 8.844, p = 0.003).

Structured PICO

Does a lower TAPSE/PASP ratio (≤ 0.35) predict increased heart failure readmissions and all-cause mortality in patients undergoing TMVR with MitraClip?

P
Population
228 consecutive patients who underwent successful transcatheter mitral valve repair (TMVR) with MitraClip for severe mitral regurgitation. Mean age 72.5 ± 11.5 years, 67.5% male.
I
Intervention
TAPSE/PASP ratio ≤ 0.35 (assessed as a non-invasive measure of right ventricular to pulmonary arterial coupling)
C
Comparator
TAPSE/PASP ratio > 0.35
O
Outcome
Composite of heart failure readmissions and all-cause mortalitycomposite

A TAPSE/PASP ratio ≤ 0.35 is a significant independent predictor of heart failure readmission and all-cause mortality in patients undergoing MitraClip implantation.

Abstract

Background: Transcatheter mitral valve repair (TMVR) is an effective therapy for high-risk patients with severe mitral regurgitation (MR) but heart failure (HF) readmissions and death remain substantial on mid-term follow-up. Recently, right ventricular (RV) to pulmonary arterial (PA) coupling has emerged as a relevant prognostic predictor in HF. In this study, we aimed to assess the prognostic value of tricuspid annular plane systolic excursion (TAPSE) to PA systolic pressure (PASP) ratio as a non-invasive measure of RV-to-PA coupling in patients undergoing TMVR with MitraClip (Abbott, CA, USA). Methods: Multicentre registry including 228 consecutive patients that underwent successful TMVR with MitraClip. The sample was divided in two groups according to TAPSE/PASP median value: 0.35. The primary combined endpoint encompassed HF readmissions and all-cause mortality. Results: Mean age was 72.5 ± 11.5 years and 154 (67.5%) patients were male. HF readmissions and all-cause mortality were more frequent in patients with TAPSE/PASP ≤ 0.35: Log-Rank 8.844, p = 0.003. On Cox regression, TAPSE/PASP emerged as a prognostic predictor of the primary combined endpoint, together with STS-Score. TAPSE/PASP was a better prognostic predictor than either TAPSE or PASP separately. Conclusions: TAPSE/PASP ratio appears as a novel prognostic predictor in patients undergoing MitraClip implantation that might improve risk stratification and candidate selection.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Trejo‐Velasco et al. (2021) studied this question. A TAPSE/PASP ratio ≤ 0.35 was associated with higher rates of heart failure readmissions and all-cause mortality in patients undergoing MitraClip therapy (Log-Rank 8.844, p = 0.003).

synapsesocial.com/papers/696564971e0bbcd078c5fa70https://doi.org/10.3390/jcm10051006
Ask AI
Helpful
Bookmark
Share
View Full Paper